2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CXCR
  5. CXCR Isoform
  6. CXCR Inhibitor

CXCR Inhibitor

CXCR Inhibitors (40):

Cat. No. Product Name Effect Purity
  • HY-P99190
    Eldelumab
    		Inhibitor
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
  • HY-P99404
    Quetmolimab
    		Inhibitor 99.90%
    Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion.
  • HY-163475
    CXCL-CXCR1/2-IN-1
    		Inhibitor 99.64%
    CXCL-CXCR1/2-IN-1 is an orally active ELR+CXCL-CXCR1/2 pathway inhibitor with an EC50 of 42.7 nM for CXCR2. CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects.
  • HY-P10552
    pCXCL8-1aa
    		Inhibitor 98.13%
    pCXCL8-1aa is an anti-inflammatory peptide. pCXCL8-1aa competitively inhibits the binding of CXCL8 to glycosaminoglycans such as heparin sulfate (HS) by binding with high affinity. This reduces the presentation of CXCL8 on the surface of vascular endothelial cells, thereby inhibiting neutrophil migration and inflammatory responses. pCXCL8-1aa can be used to study inflammatory diseases such as rheumatoid arthritis.
  • HY-149096
    CCR7 antagonist 1
    		Inhibitor 99.55%
    CCR7 antagonist 1 (30c) is a dual CXCR2 (IC50 of 11.02 μM) and CCR7 (IC50 of 0.43 μM) antagonist.
  • HY-N3255
    Minecoside
    		Inhibitor 99.86%
    Minecoside is a CXCR4/STAT3 inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression.
  • HY-P4109A
    vMIP-II (1-21) TFA
    		Inhibitor
    vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM).
  • HY-RS03403
    CXCR3 Human Pre-designed siRNA Set A
    		Inhibitor

    CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS03406
    CXCR4 Human Pre-designed siRNA Set A
    		Inhibitor

    CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS03407
    Cxcr4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS03400
    CXCR2 Human Pre-designed siRNA Set A
    		Inhibitor

    CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-160041A
    Olaptesed pegol sodium
    		Inhibitor
    Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment.
  • HY-RS03401
    Cxcr2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-N2573A
    Corydalmine hydrochloride
    		Inhibitor
    Corydalmine hydrochloride inhibits spore germination of some plant pathogenic as well as saprophytic fungi. Corydalmine hydrochloride acts as an oral analgesic agent, exhibiting potent analgesic activity. Corydalmine hydrochloride alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway.
  • HY-164682
    AMD 3329 octahydrobromide
    		Inhibitor
    AMD 3329 octahydrobromide is a potent and selective anti-HIV-1 and HIV-2 compound with activity to inhibit viral replication. AMD 3329 blocks viral invasion by binding to the chemokine receptor CXCR4. AMD 3329 exhibits EC50 values as low as 0.8 and 1.6 nM when inhibiting HIV-1 and HIV-2 replication, showing better antiviral efficacy than AMD3100. AMD 3329 significantly inhibits the binding of specific CXCR4 monoclonal antibodies and the Ca(2+) flux induced by SDF-1alpha. AMD 3329 is also able to effectively interfere with virus-induced syncytium formation, with an EC50 value of 12 nM.
  • HY-RS03408
    Cxcr4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cxcr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-P4810
    Polyphemusin II-Derived Peptide
    		Inhibitor
    Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4.
  • HY-153464
    CXCR4-IN-1
    		Inhibitor
    CXCR4-IN-1 (Example C5) is a CXCR4 inhibitor (IC50: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc.
  • HY-RS03399
    Cxcr1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cxcr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS03398
    Cxcr1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cxcr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.